Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2024
Business Overview: Developer, manufacturer, and seller of life science technologies and products for research, pharmaceutical discovery, and bioproduction. Operations span the U.S., Europe, and China.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenues | $21.97M | $25.36M | $69.58M | $84.10M |
| Gross Profit | $12.77M | $14.73M | $40.76M | $49.75M |
| Gross Margin | 58.1% | 58.1% | 58.6% | 59.2% |
| Operating Loss | $(1.87M) | $(0.93M) | $(6.22M) | $1.61M |
| Net Loss | $(4.80M) | $(1.24M) | $(12.42M) | $(1.60M) |
| Diluted EPS | $(0.11) | $(0.03) | $(0.29) | $(0.04) |
| Cash & Equivalents | $4.57M | (Balance Sheet: Dec 31, 2023: $4.28M) | ||
| Total Debt (Gross) | $38.3M | (Balance Sheet: Dec 31, 2023: $37.1M) | ||
| Operating Cash Flow (9M) | $(0.29M) | (9M 2023: $9.73M) |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 13.4% in Q3 and 17.3% for the nine months ended September 30, 2024, compared to the prior year. Management attributes this to softening global demand, particularly from CROs, academic institutions, and distributors in China and the Asia-Pacific region.
- Operating Performance: The company shifted from an operating profit of $1.61M in the first nine months of 2023 to an operating loss of $6.22M in the same period of 2024. This was driven by lower revenues and increased operating expenses.
- Unusual Items:
- Pension Settlement: A non-cash charge of $1.24M was recorded in Q3 2024 related to the settlement of a UK defined benefit plan.
- Equity Securities: The company sold HRGN shares for $1.9M, recording a loss of $1.6M for the nine months ended September 30, 2024. In contrast, Q3 2023 included a $1.2M unrealized gain on these securities.
- Restructuring: $0.6M in restructuring costs were incurred in the first nine months of 2024, primarily for headcount reductions.
- Cash Flow: Operating cash flow turned negative ($0.29M outflow) for the nine months ended September 30, 2024, compared to a $9.73M inflow in the prior year period, primarily due to the decline in net income.
Guidance, Outlook, and Risks
- Liquidity Constraints: The company is currently unable to make additional borrowings under its $25.0M revolving credit facility due to net leverage ratio requirements. Borrowing capacity will remain restricted until the delivery of financial statements for the fiscal year ending December 31, 2024.
- Debt Covenants: The company is currently in compliance with financial covenants. However, an August 2024 amendment to the Credit Agreement increased the interest rate margin by 50bps while the net leverage ratio exceeds 3.0.
- Outlook: Management expects available cash and cash generated from operations to be sufficient to finance operations and service debt for at least the next 12 months, contingent on successful execution of cost containment and revenue growth plans.
- Risks: Key risks include the inability to access additional credit, continued softening of international markets (especially China), and the impact of inflationary and interest rate pressures.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the company's ability to meet the net leverage ratio requirements to unlock the revolving credit facility upon filing the 2024 10-K.
- Revenue Recovery: Monitor subsequent quarterly reports for signs of demand recovery in the CRO and academic sectors, particularly in the Greater China region.
- Cash Burn Rate: Assess the sustainability of the current cash position ($4.57M) against operating losses and debt service obligations given the restricted access to the credit line.
- Restructuring Impact: Track the realization of cost savings from the $0.6M restructuring initiative and headcount reductions.
- ERTC Liability: Note the $3.2M in Employee Retention Tax Credit refunds held in "Other Current Liabilities" pending final determination of recognizability.